Abstract
Zeria and Yamanouchi are co-developing Z-338, a thiazole-4-carboxamide derivative with prokinetic activities, as a potential treatment for dyspepsia and gastric motility disorders. This compound is currently in phase II clinical trials.
MeSH terms
-
Animals
-
Benzamides / chemical synthesis
-
Benzamides / metabolism
-
Benzamides / pharmacology*
-
Biological Availability
-
Cholinesterase Inhibitors / administration & dosage
-
Cholinesterase Inhibitors / metabolism
-
Cholinesterase Inhibitors / pharmacokinetics
-
Clinical Trials, Phase II as Topic
-
Dogs
-
Drug Administration Routes
-
Drug Evaluation, Preclinical / methods
-
Drug Industry*
-
Drugs, Investigational
-
Dyspepsia / drug therapy
-
Gastrointestinal Agents / chemical synthesis
-
Gastrointestinal Agents / metabolism
-
Gastrointestinal Agents / pharmacology
-
Gastrointestinal Diseases / drug therapy
-
Gastrointestinal Motility / drug effects
-
Guinea Pigs
-
Humans
-
Hypnotics and Sedatives / administration & dosage
-
Hypnotics and Sedatives / metabolism
-
Hypnotics and Sedatives / pharmacokinetics
-
Molecular Structure
-
Multicenter Studies as Topic
-
Rats
-
Receptor, Muscarinic M1 / drug effects
-
Receptor, Muscarinic M1 / physiology
-
Receptor, Muscarinic M1 / therapeutic use
-
Receptor, Muscarinic M2 / drug effects
-
Receptor, Muscarinic M2 / physiology
-
Receptor, Muscarinic M2 / therapeutic use
-
Sweden
-
Thiazoles / chemical synthesis
-
Thiazoles / metabolism
-
Thiazoles / pharmacology*
-
Xenopus
Substances
-
Benzamides
-
Cholinesterase Inhibitors
-
Drugs, Investigational
-
Gastrointestinal Agents
-
Hypnotics and Sedatives
-
Receptor, Muscarinic M1
-
Receptor, Muscarinic M2
-
Thiazoles
-
Z 338